Public Employees Retirement System of Ohio raised its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 17.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,707 shares of the biopharmaceutical company’s stock after buying an additional 3,844 shares during the quarter. Public Employees Retirement System of Ohio owned 0.05% of Xencor worth $543,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of XNCR. FMR LLC lifted its stake in Xencor by 77.7% during the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after buying an additional 2,924,510 shares in the last quarter. State Street Corp lifted its stake in Xencor by 17.5% during the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after buying an additional 148,136 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Xencor by 57.4% during the first quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock valued at $6,863,000 after buying an additional 104,638 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Xencor by 48.1% during the second quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after buying an additional 93,975 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Xencor by 5.6% during the second quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock valued at $35,913,000 after buying an additional 90,094 shares in the last quarter. 76.70% of the stock is owned by institutional investors.

A number of analysts have commented on XNCR shares. ValuEngine lowered shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. Canaccord Genuity set a $36.00 price target on shares of Xencor and gave the stock a “buy” rating in a research report on Monday, October 23rd. BidaskClub lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $28.67.

In related news, major shareholder John S. Stafford III purchased 43,500 shares of the stock in a transaction on Friday, August 18th. The shares were bought at an average price of $19.93 per share, for a total transaction of $866,955.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder John S. Stafford III purchased 79,035 shares of the stock in a transaction on Thursday, August 17th. The shares were bought at an average price of $20.47 per share, for a total transaction of $1,617,846.45. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 427,209 shares of company stock worth $8,537,686. Insiders own 4.14% of the company’s stock.

Shares of Xencor, Inc. (NASDAQ:XNCR) opened at $21.03 on Monday. Xencor, Inc. has a 52-week low of $18.55 and a 52-week high of $29.38.

TRADEMARK VIOLATION WARNING: “Public Employees Retirement System of Ohio Has $543,000 Holdings in Xencor, Inc. (XNCR)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-has-543000-holdings-in-xencor-inc-xncr/1699619.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.